{"registry": "ISRCTN", "registryId": "ISRCTN82375386", "source": "https://www.isrctn.com/ISRCTN82375386", "apiSource": "https://www.isrctn.com/api/trial/ISRCTN82375386/format/default", "fetchedAt": "2026-10-07T17:01:27.778981Z", "license": "CC BY 4.0", "licenseSource": "https://www.isrctn.com/page/faqs#licence-to-post", "study": {"title": "QUASAR (stands for QUick and Simple And Reliable).  UKCCCR randomised study of adjuvant chemotherapy in colon and rectal cancer", "scientificTitle": "QUASAR (stands for QUick and Simple And Reliable).  UKCCCR randomised study of adjuvant chemotherapy in colon and rectal cancer", "acronym": "QUASAR", "hypothesis": "Reliable assessment, among patients who have undergone apparently curative surgery for colorectal cancer, of the balance of benefits and risks of adjuvant chemotherapy.  Patients for whom there is substantial uncertainty whether or not they should receive chemotherapy are randomised between chemotherapy versus open control.  Patients considered to have a clear indication for chemotherapy were randomised (until 1997) between different chemotherapy regimens.  Of those who receive adjuvant chemotherapy, the four treatment regimens were:\n1. 5-FU (370 mg/m^2) + 175 mg L-folinic acid + levamisole \n 2. 5-FU (370 mg/m^2) + 175 mg L-folinic acid + placebo \n3. 5-FU (370 mg/m^2) + 25 mg L-folinic acid + levamisole \n4. 5-FU (370 mg/m^2) + 25 mg L-folinic acid + placebo\ngiven either daily for five days every four weeks for a total of six cycles, or once-weekly for thirty weeks. Since 1997 patients allocated chemotherapy all receive arm four (without placebo).", "primaryOutcome": "Survival, recurrence, cost-effectiveness, quality of life.", "secondaryOutcome": "Not provided at time of registration", "intervention": "\n\tChemotherapy versus open control\n\tDrug\n\tNot Specified\n\tChemotherapy: Fluorouracil, L-folinic acid and levamisole\n      ", "condition": "\n\tColorectal Cancer\n\tCancer\n\tColorectal Cancer\n      ", "studyDesign": "Randomised controlled trial", "overallEndDate": "2003-10-31T00:00:00.000Z", "clinicalTrialsGovNumber": "NCT00005586", "lastUpdated": "2018-10-17T08:41:24.799Z", "eligibility": {"inclusion": "Patients who have had apparently curative surgery for Duke's A, B or C colorectal cancer within the past three months are eligible for inclusion in QUASAR.", "exclusion": "There are no definite exclusion criteria but patients must be considered fit by their clinicians to undergo six months chemotherapy.", "ageRange": "Not Specified", "gender": "Not Specified", "participantType": "Patient"}, "recruitment": {"recruitmentStart": "1994-05-01T00:00:00.000Z", "recruitmentEnd": "2003-10-31T00:00:00.000Z", "recruitmentStatusOverride": "", "recruitmentStartStatusOverride": "", "targetEnrolment": "5000", "totalFinalEnrolment": ""}, "countries": ["United Kingdom", "England"], "locations": [{"name": "University of Birmingham Clinical Trials Unit", "city": "Birmingham", "state": "", "country": "United Kingdom", "zip": "B15 2RR"}], "sponsors": [{"organisation": "Medical Research Council (MRC) (UK)", "sponsorType": "Research council"}], "funders": [{"name": "Medical Research Council", "fundRef": "http://dx.doi.org/10.13039/501100000265"}]}, "studySha256": "f3639a718355dfe9c3b370d6a35c92c182b539d15e586f18a7371a61ef2e4771"}